Preventing Recurrent Clostridioides difficile Infections with Fecal Microbiota-Based Therapies : Episode 12
Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice
Matthew D. Sims, MD, PhD, FACP, FIDSA, discusses how fecal microbiota transplantation therapies are administered and shares his clinical experience.
EP: 1.Epidemiology of C. difficile Infections in the US
EP: 2.Recurrence of C. Difficile Infections
EP: 3.Risk Factors for C. difficile Infections
EP: 4.Patients at Risk for Recurrent C. difficile Infections and the Role of Environmental Factors
EP: 5.Diagnostic Tests for C. difficile Infections
EP: 6.Treatment Guidelines for C. difficile Infection
EP: 7.Factors Contributing to C. difficile Infection Recurrence
EP: 8.Managing C. difficile Infections in the Clinic
EP: 9.Contribution of Unnecessary and Prolonged Antibiotic Use to Recurrent C. difficile Infections
EP: 10.Fecal Microbiota Transplantation for C. difficile Infections
EP: 11.Recent Fecal Microbiota Transplant Approvals for C. difficile Infections
Now Viewing
EP: 12.Administration of FDA-Approved Fecal Microbiota Transplants for C. difficile Infections in Clinical Practice
EP: 13.Data on Fecal Microbiota, Live-JSLM (RBL) for C. difficile Infections
EP: 14.ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
EP: 15.Safety of Fecal Microbiota Options and Transfer of Food-Borne Allergens
EP: 16.Utilization of Fecal Microbiota Transplant Products in Clinical Practice
Video content above is prompted by the following:
- How are these FMT therapies administered?
- What has your experience been with administering each of these therapies?
- What have you heard from your patients?
Recent Videos
Related Content
